@misc{oai:repo.qst.go.jp:00066013,
 author = {李, 惠子 and 長谷川, 純崇 and 李 惠子 and 長谷川 純崇},
 month = {Oct},
 note = {Peritoneal metastasis of gastric cancer (PMGC) has extremely poor prognosis, however, there is no effective therapeutics has been established. About 20% of GC is reported as HER2-overexpressed (HER2+), and trastuzumab, a humanized anti-HER2 monoclonal antibody, has been used for the treatment for HER2+ PMGC. Radioimmunotherapy (RIT), the internal radiotherapy using radioisotope (RI)-labeled cancer specific antibody, has huge advantage in targeting metastatic cancer. Recently, alpha-RIT, using alpha emitting RI, is getting higher attention, because the alpha particle has high cell cytotoxicity and its short range can prevent damages to untargeted tissues. Astatine 211 (<SUP>211</SUP>At) is one of the useful alpha-RI. In this study, we investigated the cell cytotoxicity and therapeutic efficacy of RIT with <SUP>211</SUP>At-trastuzumab against of HER2+ PMGC both in vitro and in vivo. We will discuss the possibility of alpha-RIT with <SUP>211</SUP>At-trastuzumab as a new effective therapeutic for HER2+ PMGC., 第75回日本癌学会学術総会},
 title = {HER2高発現胃がん腹膜播種に対するα線放出核種211Atを用いた放射免疫療法},
 year = {2016}
}